Front Line Therapy For Multiple Myeloma And Mantle Cell Lymphoma: The Role of Hematopoietic Cell Transplantation and Proteasome Inhibition Therapies

The management of multiple myeloma has changed dramatically over the past 2 decades. Testing of new treatment options continues at a rapid pace. The advances have resulted in improved survival rates not only in clinical trial participants, but these benefits have been applied to general practice and survival rates are improving in population-based studies as well. Although cure largely remains beyond a realistic prospect, durable control of disease is achievable in the majority of patients.

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Multiple Myeloma: An Evidence-Based Review

The American Society for Blood and Marrow Transplantation (ASBMT) believes that development of a series of evidence-based reviews will address an important need of both the transplant community and a larger non-transplant audience to codify the current state of knowledge of the role of hematopoietic stem cell transplantation (SCT) in the management of various diseases.